Safety, Efficacy and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected with SARS-CoV-2 - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Kidney International Reports Année : 2022

Safety, Efficacy and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected with SARS-CoV-2

Résumé

Introduction - The efficacy of nirmatrelvir-ritonavir (NR; Paxlovid, Pfizer, New York, NY) to decrease the risk of progression to severe COVID-19 in high-risk patients has been demonstrated. However, evidence in infected kidney transplant recipients (KTRs) is lacking. Moreover, NR has significant and potentially harmful interactions with calcineurin inhibitors (CNIs). Methods - In this single-center retrospective study, we included all KTRs treated with NR from April 28 to June 3, 2022. A standard management strategy of CNI dose adaptation (discontinuation of tacrolimus 12 hours before the start of NR and administration of 20% of the cyclosporine dose) and laboratory follow-up was applied. Results - A total of 14 patients were included. Compared with day-0 (day before NR initiation), day-7 plasma creatinine concentrations and SARS-CoV-2 viral loads were similar ( = 0.866) and decreased ( = 0.002), respectively. CNI trough concentrations at the end of the treatment were satisfactory, nonetheless, with high individual variability. After a median follow-up time of 34 days, no death or viral pneumonia were observed. Nevertheless, 2 patients experienced early SARS-CoV-2 infection relapses (at day-10 and day-21) associated with an increase in SARS-CoV-2 viral loads. Conclusion - NR can be used in KTRs but requires a strict protocol of drug adaptation. We observed 2 cases of early relapse after NR treatment that need further investigations.
Fichier principal
Vignette du fichier
Devresse.pdf (841.82 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03789825 , version 1 (27-09-2022)
hal-03789825 , version 2 (05-10-2022)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Arnaud Devresse, Sébastien Briol, Julien de Greef, Florian Lemaitre, Lidvine Boland, et al.. Safety, Efficacy and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected with SARS-CoV-2. Kidney International Reports, 2022, 7 (11), pp.2356-2363. ⟨10.1016/j.ekir.2022.08.026⟩. ⟨hal-03789825v2⟩
142 Consultations
34 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More